Cervical cancer is one of the most common cancers in women living in sub-Saharan Africa, with roughly 110,000 women diagnosed annually; of these women, about 66% will die from the disease. Women living with HIV (WLHIV) are up to six times more likely to develop persistent precancerous lesions and progress to cervical cancer, often with more aggressive forms and higher mortality.

Launched in May 2018 to address this challenge, Go Further is an innovative public–private partnership between the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR), the George W. Bush Institute, the Joint United Nations Programme on HIV/AIDS (UNAIDS), Merck, and Roche. The partnership collaborates closely with PEPFAR partner governments to strategize on ways to provide services for women from prevention through the cancer journey. Go Further began working in eight countries (Botswana, Eswatini, Lesotho, Malawi, Mozambique, Namibia, Zambia, and Zimbabwe), and expanded services to four additional countries (Ethiopia, Kenya, Tanzania, and Uganda) in fiscal year (FY) 2021. The objectives are to screen all WLHIV on ART between the ages of 25 and 49 for cervical cancer, and to treat pre-invasive cervical cancer lesions to prevent progression to cervical cancer.

### Namibia Program Highlights

<table>
<thead>
<tr>
<th>Fiscal Year</th>
<th>Funding Amount</th>
<th>Cervical Cancer Screening Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>FY19</td>
<td>$2,000,000</td>
<td>40,000</td>
</tr>
<tr>
<td>FY20</td>
<td>$977,205</td>
<td>46,271</td>
</tr>
<tr>
<td>FY21</td>
<td>$500,000</td>
<td>48,576</td>
</tr>
<tr>
<td>FY22</td>
<td>$1,250,000</td>
<td>48,686</td>
</tr>
<tr>
<td>FY23</td>
<td>$1,000,000</td>
<td>46,937</td>
</tr>
</tbody>
</table>

### Country Context

- **Total Population (July 2022 est.)**
  - World Factbook: 2,727,409

- **Women Aged 15–49 HIV Prevalence Rate (UNAIDS 2021)**
  - 15.1%

- **Age-standardized Incidence Rate (per 100,000) of Cervical Cancer Cases (Estimates for 2020)**
  - 37.4

- **Total # of Women (All Ages) On ART (PEPFAR, FY22 Q4)**
  - 133,156

Source: PEPFAR Panorama Spotlight, data.pepfar.gov
Strategic Direction for FY22

- Namibia planned to expand access of cervical cancer screening services and to increase targeted screening and treatment rates for WLHIV to 90%. In addition, PEPFAR planned to optimize cervical cancer screening through establishing a fast-track escort system and patient navigation in health facilities and pivoting the program to demand creation activities in the community by conducting targeted training of community-based partners to establish a bidirectional referral system.

- PEPFAR Namibia continued to implement the Mixed Model Approach to provide cervical cancer screening at fixed and mobile outreach services with emphasis on the outreach model by using mobile vans for outreach services.

- Other priority areas for the program included strengthening the referral system for treatment of invasive cervical cancer, to ensure that women diagnosed through the screen and treat program would be able to be treated for invasive cervical cancer, preventing further disease progression.

Implementing Partners (FY22)

- University of Washington
- Ministry of Health and Social Services
- JHPIEGO

RESULTS SUMMARY

- In FY22: 15,525 screenings were performed, representing 32% of the FY22 target; 92% of women who screened positive for precancerous lesions received treatment.

- Since FY19: 406 women screened positive for suspected invasive cervical cancer. Of the 53,732 screenings, 33,156 (61.7%) were first time screenings, 2,349 (4.37%) were follow-up screenings, and 18,227 (33.92%) were re-screens.